WO2011071730A1 - Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds - Google Patents
Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds Download PDFInfo
- Publication number
- WO2011071730A1 WO2011071730A1 PCT/US2010/058594 US2010058594W WO2011071730A1 WO 2011071730 A1 WO2011071730 A1 WO 2011071730A1 US 2010058594 W US2010058594 W US 2010058594W WO 2011071730 A1 WO2011071730 A1 WO 2011071730A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- process according
- formula
- hydrogen
- metal catalyst
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 17
- 230000008569 process Effects 0.000 title claims abstract description 16
- 239000000543 intermediate Substances 0.000 title abstract description 8
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical class C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 title abstract description 6
- 230000015572 biosynthetic process Effects 0.000 title description 7
- 238000003786 synthesis reaction Methods 0.000 title description 6
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 16
- 239000003054 catalyst Substances 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 229910052763 palladium Inorganic materials 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011260 aqueous acid Substances 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 239000003759 ester based solvent Substances 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- -1 carboxamide compounds Chemical class 0.000 description 4
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 229940102001 zinc bromide Drugs 0.000 description 2
- BQLGCIUPZRALSH-UHFFFAOYSA-N 2-methylsulfonylpyridine-4-carbonitrile Chemical compound CS(=O)(=O)C1=CC(C#N)=CC=N1 BQLGCIUPZRALSH-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 0 C*1C2=C*C=C(C(*(C)(C)C(*)(*)*)=O)C2=C*1 Chemical compound C*1C2=C*C=C(C(*(C)(C)C(*)(*)*)=O)C2=C*1 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000002473 indoazoles Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
Definitions
- This invention relates to novel processes for preparing compounds of the formula (I):
- Indazole and azaindazole substituted compounds of formula II have been described as inhibitors of CCR1. Examples of such compounds are reported in WO 2009/134666 and WO 2010/036632. The compounds are useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.
- amine intermediate VI An essential intermediate in the above described synthesis of indazole and azaindazole substituted carboxamide compounds is the amine intermediate VI.
- the known synthesis of the amine intermediate VI involves the conversion of the cyano compound below to the corresponding amine and is done by a 2-step process involving 1) reduction with sodium borohydride/trifluoroacetic acid/zinc bromide and in-situ tert- butoxycarbonylation,
- an ionic salt comprising: i) hydrogenating a compound of the formula (II) using a metal catalyst, preferably a Pd or Ni based catalyst, more preferably Palladium over Carbon, most preferably 10%
- Pd/C with water even more preferably 10% Pd/C/50% water
- hydrogen preferably hydrogen at pressures of 15-1000 psi, preferably 100-200 psi for 2-20 hours, preferably 7 hours, at 0-100 ° C, preferably 25 ° C
- an acid solution or gas preferably concentrated aqueous hydrochloric acid
- the reaction is performed in a solvent chosen from an alcohol solvent, ester solvents, aqueous acids, ethers and toluene or other aromatic hydrocarbons solvents, preferably methanol, ethanol, isopropanol, or acetic acid, more preferably methanol, to provide a compound of the formula (I):
- R is hydrogen or Cl-10 alkyl, preferably Cl-5 alkyl, more preferably methyl.
- alkyl refers to a saturated aliphatic radical containing from one to ten carbon atoms.
- Alkyl refers to both branched and unbranched alkyl groups.
- a hydrogenation vessel is charged with 2-(methanesulfonyl)-4-cyanopyridine (8.00 g, 43.9 mmol), 10 wt.% Pd/C (50% water) (800 mg, 0.377 mmol) and MeOH (48 mL).
- the mixture is hydrogenated under 100 psi of hydrogen at 25 ° C for 7 hours.
- the reaction mixture is filtered to remove the catalyst, using MeOH to rinse, and the filtrate is concentrated to a volume of 24 mL. Isopropanol (48 mL) is added, followed by concentrated hydrochloric acid (4.03 mL, 48.3 mmol, 1.1 eq).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010800504234A CN102596908A (zh) | 2009-12-08 | 2010-12-01 | 用于制备取代的吲唑和氮杂吲唑化合物的中间体的合成方法 |
| IN5081DEN2012 IN2012DN05081A (uk) | 2009-12-08 | 2010-12-01 | |
| MX2012006524A MX2012006524A (es) | 2009-12-08 | 2010-12-01 | Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindol. |
| BR112012013582A BR112012013582A2 (pt) | 2009-12-08 | 2010-12-01 | processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos |
| CA2782384A CA2782384A1 (en) | 2009-12-08 | 2010-12-01 | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| JP2012543154A JP2013512954A (ja) | 2009-12-08 | 2010-12-01 | 置換インダゾール及びアザインダゾール化合物の生成に有効な中間体の合成方法 |
| EP10787651A EP2509952A1 (en) | 2009-12-08 | 2010-12-01 | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| AU2010328480A AU2010328480A1 (en) | 2009-12-08 | 2010-12-01 | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| EA201200820A EA201200820A1 (ru) | 2009-12-08 | 2010-12-01 | Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов |
| IL219274A IL219274A0 (en) | 2009-12-08 | 2012-04-19 | Process for synthesis of intermediates useful for making substituted indazole and azindazole compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26753809P | 2009-12-08 | 2009-12-08 | |
| US61/267,538 | 2009-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011071730A1 true WO2011071730A1 (en) | 2011-06-16 |
Family
ID=43416915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2010/058594 WO2011071730A1 (en) | 2009-12-08 | 2010-12-01 | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110137042A1 (uk) |
| EP (1) | EP2509952A1 (uk) |
| JP (1) | JP2013512954A (uk) |
| KR (1) | KR20120101667A (uk) |
| CN (1) | CN102596908A (uk) |
| AR (1) | AR079324A1 (uk) |
| AU (1) | AU2010328480A1 (uk) |
| BR (1) | BR112012013582A2 (uk) |
| CA (1) | CA2782384A1 (uk) |
| CL (1) | CL2012001300A1 (uk) |
| EA (1) | EA201200820A1 (uk) |
| IL (1) | IL219274A0 (uk) |
| IN (1) | IN2012DN05081A (uk) |
| MX (1) | MX2012006524A (uk) |
| TW (1) | TW201144282A (uk) |
| WO (1) | WO2011071730A1 (uk) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8063065B2 (en) | 2008-09-26 | 2011-11-22 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as CCR1 receptor antagonists |
| US8293917B2 (en) | 2008-05-06 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CCR1 antagonists |
| US8546442B2 (en) | 2010-12-23 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as CCR1 receptor antagonists |
| US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
| US8927550B2 (en) | 2009-10-27 | 2015-01-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as CCR1 receptor antagonists |
| US9056858B2 (en) | 2009-10-21 | 2015-06-16 | Boehringer Ingelheim International Gmbh | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5216912B2 (ja) | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004043924A1 (en) * | 2002-11-12 | 2004-05-27 | Astrazeneca Ab | 2-pyridone derivatives as inhibitors of neutrophile elastase |
| WO2007028083A2 (en) * | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| WO2009024585A2 (en) * | 2007-08-21 | 2009-02-26 | Biofocus Dpi Limited | Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis |
| WO2009134666A1 (en) | 2008-04-29 | 2009-11-05 | Boehringer Ingelheim International Gmbh | Indazole compounds as ccr1 receptor antagonists |
| WO2010036632A1 (en) | 2008-09-26 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as ccr1 receptor antagonists |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242931A (en) * | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
| CA1338625C (en) * | 1988-06-09 | 1996-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| US5750542A (en) * | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| US5616537A (en) * | 1992-07-03 | 1997-04-01 | Kumiai Chemical Industry Co., Ltd. | Condensed heterocyclic derivatives and herbicides |
| GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| WO1995000509A1 (fr) * | 1993-06-25 | 1995-01-05 | Kumiai Chemical Industry Co., Ltd. | Derive d'indazolesulfonyluree, son utilisation et intermediaire pour sa production |
| CA2207201A1 (en) * | 1994-12-06 | 1996-06-13 | Caroline Henry | Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists |
| GB9519563D0 (en) * | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9523583D0 (en) * | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| GB9615449D0 (en) * | 1996-07-23 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
| YU25400A (sh) * | 1997-11-04 | 2003-07-07 | Pfizer Products Inc. | Terapeutski aktivna jedinjenja sa indazolom |
| US6331640B1 (en) * | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| JP2003502314A (ja) * | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | 化合物 |
| AU5895500A (en) * | 1999-06-29 | 2001-01-31 | Cor Therapeutics, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| GB0030303D0 (en) * | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030305D0 (en) * | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030306D0 (en) * | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030304D0 (en) * | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US7058826B2 (en) * | 2000-09-27 | 2006-06-06 | Amphus, Inc. | System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment |
| US20020052373A1 (en) * | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| ATE455104T1 (de) * | 2001-11-01 | 2010-01-15 | Icagen Inc | Pyrazolamide zur anwendung in der behandlung von schmerz |
| WO2003101968A1 (fr) * | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Compose de pyrazole et composition medicinale le contenant |
| SE0203825D0 (sv) * | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| NZ542671A (en) * | 2003-03-12 | 2008-12-24 | Celgene Corp | 7-Amido-isoindolyl compounds and their pharmaceutical uses |
| US7129264B2 (en) * | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US20040220170A1 (en) * | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| EP1664052B1 (en) * | 2003-08-15 | 2009-02-18 | AstraZeneca AB | Fused heterocycles as inhibitors of glutamate racemase (muri) |
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| SE0302487D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0504828D0 (en) * | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| CA2599555A1 (en) * | 2005-03-16 | 2006-09-21 | Basf Aktiengesellschaft | Biphenyl-n-(4-pyridyl) methylsufonamides |
| CA2609053C (en) * | 2005-05-17 | 2017-04-25 | Sarcode Corporation | Compositions and methods for treatment of eye disorders |
| US20080262040A1 (en) * | 2005-10-25 | 2008-10-23 | Smithkline Beecham Corporation | Chemical Compounds |
| EP2004643A1 (en) * | 2006-03-31 | 2008-12-24 | Novartis AG | Organic compounds |
| PE20081775A1 (es) * | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
| CA2699631A1 (en) * | 2007-10-31 | 2009-05-07 | Nissan Chemical Industries, Ltd. | Pyridazinone compounds and p2x7 receptor inhibitors |
| JP5411927B2 (ja) * | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１アンタゴニストとしてのピラゾール化合物 |
-
2010
- 2010-12-01 CN CN2010800504234A patent/CN102596908A/zh active Pending
- 2010-12-01 WO PCT/US2010/058594 patent/WO2011071730A1/en active Application Filing
- 2010-12-01 CA CA2782384A patent/CA2782384A1/en not_active Abandoned
- 2010-12-01 KR KR1020127014239A patent/KR20120101667A/ko not_active Application Discontinuation
- 2010-12-01 IN IN5081DEN2012 patent/IN2012DN05081A/en unknown
- 2010-12-01 MX MX2012006524A patent/MX2012006524A/es not_active Application Discontinuation
- 2010-12-01 US US12/957,483 patent/US20110137042A1/en not_active Abandoned
- 2010-12-01 EA EA201200820A patent/EA201200820A1/ru unknown
- 2010-12-01 BR BR112012013582A patent/BR112012013582A2/pt not_active IP Right Cessation
- 2010-12-01 AU AU2010328480A patent/AU2010328480A1/en not_active Abandoned
- 2010-12-01 EP EP10787651A patent/EP2509952A1/en not_active Withdrawn
- 2010-12-01 JP JP2012543154A patent/JP2013512954A/ja active Pending
- 2010-12-07 TW TW099142648A patent/TW201144282A/zh unknown
- 2010-12-07 AR ARP100104528A patent/AR079324A1/es unknown
-
2012
- 2012-04-19 IL IL219274A patent/IL219274A0/en unknown
- 2012-05-18 CL CL2012001300A patent/CL2012001300A1/es unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004043924A1 (en) * | 2002-11-12 | 2004-05-27 | Astrazeneca Ab | 2-pyridone derivatives as inhibitors of neutrophile elastase |
| WO2007028083A2 (en) * | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| WO2009024585A2 (en) * | 2007-08-21 | 2009-02-26 | Biofocus Dpi Limited | Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis |
| WO2009134666A1 (en) | 2008-04-29 | 2009-11-05 | Boehringer Ingelheim International Gmbh | Indazole compounds as ccr1 receptor antagonists |
| WO2010036632A1 (en) | 2008-09-26 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as ccr1 receptor antagonists |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8293917B2 (en) | 2008-05-06 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CCR1 antagonists |
| US8063065B2 (en) | 2008-09-26 | 2011-11-22 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as CCR1 receptor antagonists |
| US8163918B2 (en) | 2008-09-26 | 2012-04-24 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as CCR1 receptor antagonists |
| US8338610B2 (en) | 2008-09-26 | 2012-12-25 | Boehringer Ingelheim International Gmbh | Pyridinyl compounds useful as intermediates |
| US9056858B2 (en) | 2009-10-21 | 2015-06-16 | Boehringer Ingelheim International Gmbh | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists |
| US8927550B2 (en) | 2009-10-27 | 2015-01-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as CCR1 receptor antagonists |
| US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
| US8546442B2 (en) | 2010-12-23 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as CCR1 receptor antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110137042A1 (en) | 2011-06-09 |
| EA201200820A1 (ru) | 2013-01-30 |
| KR20120101667A (ko) | 2012-09-14 |
| TW201144282A (en) | 2011-12-16 |
| AR079324A1 (es) | 2012-01-18 |
| JP2013512954A (ja) | 2013-04-18 |
| MX2012006524A (es) | 2012-07-17 |
| AU2010328480A1 (en) | 2012-05-17 |
| CA2782384A1 (en) | 2011-06-16 |
| CL2012001300A1 (es) | 2012-09-07 |
| IL219274A0 (en) | 2012-06-28 |
| IN2012DN05081A (uk) | 2015-10-09 |
| EP2509952A1 (en) | 2012-10-17 |
| BR112012013582A2 (pt) | 2016-07-05 |
| CN102596908A (zh) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011071730A1 (en) | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds | |
| EP2300431B1 (en) | Process for the manufacture of an intermediate in the synthesis of dabigatran | |
| KR20170027792A (ko) | 방향족 1급 디아민의 제조 방법 | |
| EP2524909B1 (en) | Preparation method of 4-aminomethylbenzoic acid | |
| CN108610279B (zh) | 一种新型合成顺式-1-苄基-3-甲氨基-4-甲基-哌啶的方法 | |
| KR101757683B1 (ko) | 트리엔틴 및 이의 염산염의 신규 제조 방법 | |
| CA3132399A1 (en) | Synthesis of 4-amino-5-methyl-1h-pyridin-2(1h)-on (intermediate compound for the synthesis of the mr antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine | |
| KR100722981B1 (ko) | 촉매 수소화 반응에 의한 트란스-4-메틸시클로헥실아민의제조방법 | |
| CN101209989A (zh) | 用于制备2-氨基甲基哌啶的方法 | |
| CN111170932A (zh) | 一种2-氨甲基-5-三氟甲基吡啶盐的制备方法 | |
| JP3890452B2 (ja) | アミノメチルピリジン化合物の製造法 | |
| IL267481A (en) | Catalytic hydrogenation of nitriles | |
| JP4755829B2 (ja) | ピロリジン誘導体の製造方法 | |
| US4376215A (en) | Process for the production of 4-aminobutyramide hydrochloride | |
| CN117402083A (zh) | 一种亚氨基腙中间体的制备方法 | |
| KR20170093821A (ko) | 이달로피르딘의 제조 방법 | |
| TWI332954B (uk) | ||
| JP4896476B2 (ja) | メチルオキシメチルアミノピリジン誘導体及びその製造方法 | |
| JP2015227293A (ja) | ２，３−ジハロゲノアニリンの製造方法 | |
| EP1212289A1 (en) | Preparation of halogenated primary amines | |
| EP2778165A1 (en) | Synthesis of a serotonin reuptake inhibitor | |
| JP5797108B2 (ja) | ２−インダノールの製造方法 | |
| JP2004083495A (ja) | ２−アミノメチルピリミジン及びその塩の製造法 | |
| JP2004067592A (ja) | アミノ−フェニルピペリジンの製造法 | |
| JP2000256283A (ja) | ハロゲン含有アミノメチル化合物の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 201080050423.4 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10787651 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 219274 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2010328480 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2010787651 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2010328480 Country of ref document: AU Date of ref document: 20101201 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2012001300 Country of ref document: CL |
|
| ENP | Entry into the national phase |
Ref document number: 2782384 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 20127014239 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2012543154 Country of ref document: JP Ref document number: MX/A/2012/006524 Country of ref document: MX |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 5081/DELNP/2012 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12012501153 Country of ref document: PH |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 201200820 Country of ref document: EA |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012013582 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 112012013582 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120605 |